Viracta Therapeutics Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $5 to $3.
Viracta Therapeutics Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $5 to $3.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.